![]() The operations, employees and directors of CloudTag Active Limited have, during the course of this year, been transferred to CT Technology Services Limited. The purpose of CT Technology Services Limited is to facilitate the ongoing development of the Company's technology. CT Technology Services Limited was incorporated in England and Wales on 2 June 2016 and became a wholly owned subsidiary of the Company on 22 June 2016. “…incorporated a new wholly owned UK subsidiary, CT Technology Services Limited for the development of the Company's latest technology and products. I first wrote about Massimo Ventimiglia last September when I noted that the main directors had left the main UK subsidiary at the time, CloudTag Active Limited, and been replaced by Massimo, also noting that his appointment on boards usually seemed to be just before they entered some form of insolvency proceedings.Īs it turned out, when CloudTag was forced into its confessional in December when it resumed trading (for a short while) it explained that there had been a corporate reorganisation and as part of that it had: Very pleased today.ĬloudTag – Oh dear, Massimo has turned up with his scythe: the end is nigh!ĭespite the nonsense spouted by AberdeenMan, Mr Selfridge and BrokerMan1 on LSE about CloudTag (CTAG) and its bright prospects, confirmation that the end is nigh has reached Companies House with the CEO, Amit Ben-Haim, stepping off the board of CloudTag’s UK subsidiary and being replaced by the Grim Reaper himself, Massimo Ventimiglia. There is a product, and it looks to be a very good one. ABH there and looked busy enough, between main hall and stall. Very happy to see ECG working and operational. 5 or 6 staff members, and a couple of 'invited' guests from Asia perhaps. Cloudtag well presented on main hall where speech took place. I see it is already on here, so worth looking at. Very B2B sided, and very keen for partnership. Launch via Amazon mentioned as well.ī2B clinical partners being looked at, with obese and diabetic aims. Product will be launched in Q3, with hard demonstration units to suppliers / retailers / investors and shareholders / reviewers first. They are looking at a data collection of blood pressure, heart rate etc, this is aimed at clinical partnerships (hospitals trials etc). There will be third party apps to be added to monitor blood pressure and other functions (glucose was mentioned), to a platform made for doctors review. The company has been doing patient trials and testing for the last few months, and are about to go into clinical trials as well. The platforms from the App were loaded onto a secondary device to show the ECG in operation and also the Apps main features. The App is still being completed, but it is almost ready. I can confirm the ECG works, I tested it on my own fingers and the results came up on a platform taken from the app. ![]() These are my notes on the day, first from speaking to Vicky Mahony at the stall and then to Cloudtag speaker Yuval Lange afterwards. The stall was quiet when I arrived (09.30am, with two employees in attendance, Bhav Dattani who was talking to a gentleman looking at the product, and a Vicky Mahony who was free and who I approached to get some type of update. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.Comments from LSE have just returned from the UKe-Health. The outcome of these discussions are subject to normal commercial negotiations and there can be no certainty that these discussions will lead to any contractual agreements or sales.Ī further announcement will be made in due course. The Company also confirms that it is in early stage discussions with a further potential UK distributor and an online retailer. The Company confirms that, in the normal course of business, it expects to receive its first manufactured stock of its wearable device this month as was referred to in the announcement of 24 November 2016. ("CloudTag" or the "Company")ĬloudTag (CTAG:LN), the company that brings personal monitoring to the wellbeing, fitness and digital health markets, notes the recent movement in the Company's share price and speculation that this relates to electronic correspondence from the Company's CEO which has also been made available on social media.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |